Navigation Links
Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
Date:11/4/2008

- Company Also Announces Participation in Upcoming Investor Conferences in

November -

SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced its active calendar of events for November 2008, which includes the teleconference and webcast of its third quarter 2008 financial results as well as upcoming corporate presentations at noteworthy investor conferences.

On November 6, 2008 at 5:00 p.m. Eastern time, Orexigen management will host the call and webcast to discuss the financial results for the third quarter ended September 30, 2008, and recent business highlights. The live call may be accessed by calling 800-860-2442 (domestic) or 412-858-4600 (international). The webcast can be accessed live on the investor relations section of the Company's web site at http://www.orexigen.com and will be archived for 14 days following the call.

Upcoming Corporate Presentations

Rodman & Renshaw 10th Annual Healthcare Conference

New York Palace Hotel, New York

November 11, 2008

2:00 p.m. EST

Lazard Capital Markets 5th Annual Healthcare Conference

St. Regis Hotel, New York

November 18, 2008

11:25 a.m. EST

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
2. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
3. Arno Therapeutics Appoints William F. Hamilton to Board of Directors
4. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
5. Duska Therapeutics Acquires Technology for ATPotent Sperm Motility Program
6. ConvaTec Names Presidents of Wound Therapeutics and Ostomy Care Business Units
7. Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrate Superior Profile of S*BIOs Novel Anti-Cancer Drug SB939
8. Synvista Therapeutics Appoints William Federici to its Board of Directors
9. LaVoie Group Adds Cancer Therapeutics Company, Neotropix(R),to Its Life Science Agency Roster
10. Cell Therapeutics Regains Compliance with NASDAQs Minimum Bid Price Requirement
11. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... Arizona Spine & ... that earned the designation of High Performing Hospitals by U.S. News & World Report ... a hospital was significantly better than the national average in a given procedure ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... that has been named to the 2017 Inc. 500|5000, an exclusive ranking of ... three-year growth rate of 139 percent, marking the twelfth year that the company ...
(Date:8/23/2017)... Nashville, Tennessee (PRWEB) , ... August 23, 2017 ... ... expand its team to support long-term strategic growth plans, announcing the hiring of ... , A certified technology consultant and seasoned sales manager, Keelan will be working ...
(Date:8/23/2017)... ... August 23, 2017 , ... A ... of Orthopaedic Surgeons , points out that therapeutic modalities (physical therapy) is an ... According to the report, a wider scope of physical therapy options is showing ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... collection of unique masks and serums that perfectly fuse the beauty of naturally ... at the 2017 Indie Beauty Expo on August 23rd & 24th in New ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
(Date:7/31/2017)... , July 31, 2017 Three Tru-D SmartUVC ... South Korea . Tru-D, short for "Total Room Ultraviolet ... operating rooms after an environmental services (ES) professional cleans the area with ... ... "Although the BAACH ...
(Date:7/28/2017)... Inc. ("Hill-Rom") (NYSE: HRC), today announced financial results for ... updated its financial outlook for fiscal 2017. ... quarter, Hill-Rom reported earnings of $0.09 per diluted share ... period. These results reflect after-tax special items, including a ... the non-cash write-down of assets associated with the planned ...
Breaking Medicine Technology: